Purpose: We examined baseline clinical and psychosocial characteristics that predict 12-month symptom change in men and women with urological chronic pelvic pain syndromes. Materials and Methods: A total of 221 female and 176 male patients with urological chronic pelvic pain syndromes were recruited from 6 academic medical centers in the United States and evaluated at baseline with a comprehensive battery of symptom, psychosocial and illness-impact measures. Based on biweekly symptom reports, a functional clustering procedure classified participant outcome as worse, stable or improved on pain and urinary symptom severity. Cumulative logistic modeling was used to examine individual predictors associated with symptom change as well as multiple predictor combinations and interactions. Results: About 60% of participants had stable symptoms with smaller numbers (13% to 22%) showing clear symptom worsening or improvement. For pain and urinary outcomes the extent of widespread pain, amount of nonurological symptoms and poorer overall health were predictive of worsening outcomes. Anxiety, depression and general mental health were not significant predictors of Accepted for publication May 5, 2017. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
outcomes but pain catastrophizing and self-reported stress were associated with pain outcome. Prediction models did not differ between men and women and for the most part they were independent of symptom duration and age.
Conclusions: These results demonstrate for the first time in a large multisite prospective study that presence of widespread pain, nonurological symptoms and poorer general health are risk factors for poorer pain and urinary outcomes in men and women. The results point to the importance of broad based assessment for urological chronic pelvic pain syndromes and future studies of the mechanisms that underlie these findings.
Key Words: urinary bladder; prostate; prostatitis; cystitis, interstitial; pelvic pain UROLOGICAL CPPS includes idiopathic chronic pelvic pain in men and women as well as what have in the past been considered separate bladder and prostate syndromes. 1 IC/BPS has been diagnosed primarily in women 2 whereas CP/CPPS is a diagnosis exclusive to men. 3 Historically these conditions have been studied separately but recent cross-sectional studies have shown many common features in men and women with UCPPS, including the prevalence of key symptoms, psychosocial impact and some neurobiological mechanisms. 4e6 Longitudinal usual care and natural history studies suggest that IC/BPS is a relatively stable disorder with significant short-term fluctuations in severity. Only a small minority of patients are free of symptoms at a followup of 1 to 3 years. 7 Similar findings were reported in the few longitudinal studies of CP/CPPS with few remissions during a 1 to 2-year period in patients with persistent symptoms. 8e10 There are sparse data on prognostic factors that might influence the course of IC/BPS or CP/CPPS. However, some studies suggest that greater severity and persistence of symptoms are associated with continuing symptoms at followup 1 to 3 years later. 7, 8, 11 Most previous groups examined IC/BPS and CP/CPPS separately and did not evaluate non-UCPPS risk factors at baseline. Thus, to our knowledge it is not known whether nonurological and psychosocial factors such as gender, nonurological symptoms, widespread pain, life stress or a negative affect are predictive of a longitudinal symptom change in UCPPS.
The current study, which is part of the MAPP network longitudinal study of UCPPS, was done to examine a variety of demographic and clinical characteristics as predictors of a 12-month symptom change to test certain hypotheses. 1) Independent of baseline symptom severity the presence of nonurological symptoms, including widespread pain, poor general physical well-being and mood disturbance, would be associated with a greater probability of symptom worsening during 12 months. 2) Similar predictors would be determined in males and females with UCPPS, and in older and younger patients. 3) Longer chronicity of symptoms would be associated with a greater probability of symptom worsening.
MATERIALS AND METHODS
The MAPP network is a multisite prospective study funded by NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) to improve understanding of IC/BPS and CP/CPPS (supplementary Appendix 1, http://jurology.com/). Overall goals and design of the MAPP network have been previously described. 1, 12 Males and females with UCPPS enrolled at 6 discovery sites in the United States were followed for 52 weeks. Thus, the data describe a prospectively studied, usual care cohort.
Participants
Details of the recruitment methods, and inclusion and exclusion criteria were previously published. 12 Participants had to have a clinical diagnosis of IC/BPS or CP/ CPPS, pain severity at least 1 on a 0 to 10 Likert pain scale, age greater than 18 years and urinary symptoms present most of the time during 3 of the previous 6 months. Enrollment was monitored throughout to encourage the recruitment of a substantial number of men and women, and participants with a shorter (less than 2 years) and a longer (greater than 2 years) symptom duration.
Design
Following consent and enrollment participants completed all study assessments via computer during a single baseline visit. They were subsequently contacted every 2 weeks for the next 52 weeks for online ratings of current symptoms on the urinary and pain severity outcomes, and for any changes in medications.
Measures
The MAPP patient reported outcomes used in this study were described in prior publications (supplementary Appendix 2, http://jurology.com/). 5, 12 UCPPS severity was characterized on the 2 distinct dimensions of pain and urinary symptoms based on a recent psychometric analysis of MAPP baseline data. 13 A functional clustering procedure was applied to the biweekly pain and urinary severity scores to classify the overall symptom trajectory for each participant as worsening, stable or improving during the study period (supplementary Appendix 3, http://jurology.com/).
To decrease the influence of study entry effects on outcome classification we did not use the first month of symptom ratings in the clustering algorithm 14 and the symptom ratings at study week 4 were used as the baseline symptom level for modeling. Figure 1 shows individual symptom trajectories by cluster overlaid by the average symptom trajectory in the cluster.
Widespread nonurological symptoms were assessed with CMSI. 15 Widespread pain determined from the sum of pain locations, including headache, was marked on a standardized body map. 16 Also, we assessed relationship satisfaction with SEARÓ (male and female), physical and mental health quality of life with SF-12Ò PCS and MCS, respectively, 17 fatigue and sleep disturbance with the NIH (National Institutes of Health) PROMIS (Patient Reported Outcomes Measurement Information System) questionnaire, perceived life stress with PSS (Perceived Stress Scale), 18 anxiety and depression with HADS 19 and pain catastrophizing with CSQ. 20 
Statistical Analyses
We examined predictors of symptom change by cumulative logistic modeling. For each analysis a significant positive relationship indicated a greater likelihood of symptom improvement, ie the likelihood of being stable vs worse or improved vs stable. Preliminary analysis indicated that higher baseline levels of pain and urinary severity were strongly predictive of a greater likelihood of pain and urinary symptom improvement, respectively. Therefore, on all subsequent analyses the baseline level was included in the model to control for this relationship.
In a second analysis step we individually examined the association of each potential predictor variable with outcome while controlling for baseline severity. This was followed by a third set of analyses to examine interactions of predictor variables with patient gender, age and duration of illness to clarify how these variables may impact the strength of significant outcome predictors. A final set of regressions was done to test whether a combination of baseline variables would improve the prediction of outcomes.
The threshold for statistical significance was set at a conservative level of p <0.01 to minimize type 1 error. Data imputation was done to handle missing data for cluster determination. The C statistic is provided to show the relative strength of the predictive model.
RESULTS

Descriptive Data
The initial sample consisted of 233 female and 191 male patients with UCPPS, of whom 27 were excluded from analysis due to insufficient longitudinal data. The supplementary table (http://jurology. com/) shows baseline values stratified by gender.
Univariate Predictors
For pain severity 87 (21.9%), 230 (57.9%) and 80 patients (20.1%) were classified as improved, stable and worse, respectively. For urinary severity 83 (20.9%), 261 (65.7%) and 53 patients (13.3%) were improved, stable and worse, respectively. Figure 2 shows the distribution of outcomes stratified by baseline severity quartiles. Baseline severity was highly positively related to the likelihood of a more favorable outcome of pain and urinary symptoms (each OR 1.1, p <0.001). Tables 1 and 2 show univariate predictor analyses. Figure 3 shows select variables. For pain the significant predictors of a decreased likelihood of improvement included greater widespread symptoms on CMSI (OR 0.95), the body map total of nonpelvic sites (OR 0.95), and the presence of headache (OR 0.52), poorer sleep (OR 0.97) and greater fatigue (OR 0.96). Better physical and mental health shown by higher SF-12 PCS and MCS scores were associated with an increased likelihood of improvement (OR 1.06 and 1.03, respectively). Worse pain catastrophizing and perceived stress were also significantly associated with a poorer outcome (OR 0.96 and 0.96, respectively). A greater number of medication changes was associated with a decreased likelihood of improvement (OR 0.90). Older age was associated with better outcomes (OR 1.02). Gender, severity of urinary symptoms and duration of symptoms were not significantly predictive of a pain severity change.
Fewer baseline measures were significant predictors of urinary symptom outcome. Greater widespread symptoms on CMSI (OR 0.95) and the body map (OR 0.95) predicted a worse urinary outcome, as did greater fatigue (OR 0.96) and sleep disturbance (OR 0.97). SF-12 PCS predicted a greater likelihood of urinary symptom improvement (OR 1.03). Gender, duration of symptoms, baseline pain severity and the psychosocial variables were unrelated to urinary symptom change.
Predictor Interactions
For pain outcome there were no significant interactions of variables identified as significant univariate predictors with participant gender or symptom duration. For urinary symptom outcome the symptom duration but not gender interacted with the number of nonpelvic body sites and SF-12 PCS (each p <0.0001, table 3). Greater widespread pain and decreased physical quality of life were associated with a poorer outcome only in participants with less than a 2-year history of UCPPS (fig. 4) .
Multivariable Prediction
All predictor variables described as well as baseline severity were entered into exploratory multivariable, stepwise ordinal logistic regression analyses for pain and urinary outcomes (table 4) . For pain severity only SF-12 PCS and age were left in the final model in addition to baseline pain severity. For urinary severity only SF-12 PCS was left in the model in addition to baseline urinary severity. Thus, the other variables did not show enough independent association with outcomes to be included after including baseline severity and SF-12 PCS.
DISCUSSION
To our knowledge the current study is the first to prospectively examine a broad range of clinical and psychosocial patient characteristics as predictors of a longitudinal symptom change in men and women with UCPPS. About 60% of participants had stable symptoms while 13% to 22% showed clear symptom worsening or improvement. These results obtained by biweekly sampling and a sophisticated empirical subgrouping of outcomes are consistent with those of prior studies done separately of IC/BPS and CP/ CPPS. There was a general persistence of established UCPPS symptoms. A minority of patients showed sustained improvement or worsening during a 1-year period.
It is well known that enrollment in a clinical study is typically followed by symptom 14 This may be due to enrollment bias, ie participants seek out studies when symptoms are relatively increased so that decreases in the following weeks are expected due to the pattern of normal symptom fluctuation. It may also be due to study related expectation/placebo effects even if no specific treatments are involved. In our series symptom levels even at week 4 were highly positively related to 12-month improvement. This suggests a long-lasting impact of enrollment bias, which should be considered in the design of future UCPPS trials. This baseline-outcome relationship was statistically controlled for in all prediction models.
As hypothesized the extent of widespread pain and nonurological symptoms was predictive of poorer outcomes. More widespread, nonurological problems may be a marker of centralization of symptoms thought to involve a greater role for failing central nervous system modulatory mechanisms vs worsening peripheral symptom generators. 21, 22 A significant role for centralization was previously suggested for UCPPS based on persistent symptoms in the absence of obvious peripheral pathophysiology and the high degree of comorbidity with other chronic pain conditions, such as fibromyalgia, irritable bowel syndrome 23, 24 and affective disorders. 25 A second and related set of significant predictor variables for pain and urinary outcomes were those these data suggest that inflammatory processes as part of an overall stress response may be part of the centralization mechanisms involved in UCPPS. They may participate perhaps recursively as a driver and a responder to peripheral events. Future MAPP analyses of inflammatory markers and brain imaging are critical to test these potential mechanisms. Contrary to our initial hypothesis the severity of anxiety and depression symptoms was not significantly associated with the likelihood of 12-month improvement or worsening, perhaps due to the small number of participants with severe psychiatric symptomology. However, several other psychological measures had a moderate negative relationship with the likelihood of UCPPS pain improvement, including a report of current life stressors and the degree to which pain was felt to be uncontrollable and devastating (pain catastrophizing) as well as an overall lowered sense of mental well-being shown by SF-12 MCS. None of these measures was related to urinary symptom outcome. This suggests that, unlike nonurological symptoms, cognitive variables are less important to determine the clinical course of urinary symptoms compared to pain. These data suggest the potential of targeting psychosocial interventions on issues of general stress and illness coping rather than psychiatric symptoms, which is done in other chronic painful conditions.
To our knowledge the current study provides the first longitudinal data on UCPPS revealing that clinical characteristics predictive of symptom outcomes are not differentially influenced by gender. This suggests that the biological mechanisms underlying these relationships may also not be gender dimorphic. Other MAPP analyses of cross-sectional clinical and neuroimaging data also demonstrated more similarity than differences across men and women with UCPPS. 5, 28, 29 Also, neither income level as a marker of social economic status nor UCPPS chronicity was a significant predictor of outcome. However, for the urinary but not the pain severity outcome only participants with recent onset UCPPS showed a relationship of outcome with widespread symptoms and quality of life. This indicates that more chronic symptoms are highly persistent and less influenced by nonurological morbidity.
Despite the large diverse sample and the high retention rate of MAPP longitudinal data the current study has several limitations. It is important to recognize that UCPPS is a long-lasting chronic disorder and the 12-month study period is relatively short when considering the full natural history of UCPPS. Thus, the variables predicting symptom changes in the current study were related to a relatively short-term change. In addition, although this study focused on how baseline nonurological variables predict clinical outcome, it is also possible and even likely that UCPPS symptom severity is also a cause of psychological and biological stress, which can be impacted by symptomatic treatment.
In the next set of MAPP studies a longer time frame of 3 to 5 years will be examined. This should provide a more complete test of the hypotheses generated in the current series, including treatment by predictor interactions.
CONCLUSIONS
These results demonstrate in a large, multisite, prospective study that widespread pain, nonurological symptoms and poorer general health are risk factors for pain and urinary UCPPS symptom changes in men and women during the following year. Clinically this study indicates the importance of broad based assessment and intervention in patients with UCPPS and future studies aimed at determining mechanisms that underlie the relationship of widespread UCPPS symptoms. 
EDITORIAL COMMENT
We have come a long way from describing patients with "prostatitis" as "busy, nervous and meticulous" 1 or referring only men with negative expressed prostatic secretions to psychologists. Our improved understanding of UCPPS validates the physical symptoms and the psychosocial comorbidities. 2 The current thorough study reminds us that UCPPS is a multifactorial condition requiring a comprehensive nonurological approach. Through the efforts of these authors we are better equipped to validate and support patients, which in and of itself provides therapeutic benefit.
